Sunlenca 464 mg solution for injection

A Phase 2, Open-label, Multicenter, Randomized Study to Evaluate the Persistence, Safety, and Acceptability of Twice Yearly Long-acting Subcutaneous Lenacapavir for HIV Pre-Exposure Prophylaxis (PrEP) in People Who Would Benefit from PrEP

(CAbotégravir LENacapavir DUal Long Acting). Phase II, Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA